In April 2021, Alzheimer Europe has added the AUTONOMY trial to its Clinical Trials Watch - an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in Europe. The service provides information on ten phase II and seven III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease (AD).
The AUTONOMY Phase II trial (from Janssen Research & Development) has started to recruit research participants in Spain in April 2021 and is expected to recruit participants in Belgium, France, Netherlands, Sweden and UK. The purpose of the AUTONOMY study is to check how safe and effective the investigational medicine named JNJ-63733657 - an anti-tau monoclonal antibody- is in participants with early AD. Research participants will receive either an intravenous injection of placebo or JNJ-63733657 every four weeks. Further information about the CTW is available on:
http://www.alzheimer-europe.org/Research/Clinical-Trials-Watch
